NMN/NR (Nicotinamide Mononucleotide/Riboside) Safety in Children Under 12

Why Pediatric Safety Data for NMN and NR Is Essentially Absent

No published randomized controlled trial has enrolled children under 12 to test nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR). Every phase I and phase II human trial conducted to date recruited adults, and most specifically targeted individuals over 40 with age-related metabolic decline. The biological rationale for these supplements centers on correcting the NAD decline that accumulates over decades of adult life. That rationale does not translate to a child whose NAD biosynthesis machinery is operating at developmental peak capacity.

The Yoshino et al. trial published in Science (2021, N=25) remains one of the most cited human NMN studies. It enrolled postmenopausal women with prediabetes who received 250 mg/day oral NMN for 10 weeks. Muscle insulin sensitivity improved and NAD metabolite concentrations in blood rose significantly [1]. The average participant age was approximately 55. Applying those findings to a 7-year-old is not a matter of simple dose scaling; it requires separate pharmacokinetic, pharmacodynamic, and toxicology work that has not been done.

A 2023 systematic review covering all human NMN and NR trials found that the combined enrolled population across 14 trials was exclusively adult, with a median minimum enrollment age of 40 years [2]. No trial included participants under 18, let alone under 12. The absence of data is not a minor gap. For YMYL health decisions involving children, an absence of evidence is itself evidence of unacceptable uncertainty.

The FDA's January 2023 guidance letter clarified that NMN cannot be lawfully marketed as a dietary supplement because it was authorized for investigation as a drug (IND 154,258) before it was marketed as a supplement [3]. NR does not carry the same regulatory exclusion, but NR has no FDA-approved pediatric labeling, no established pediatric dosing, and no required safety monitoring framework for children.

How NAD Biology in Children Differs From Adults

Children are not small adults. NAD biology in a developing organism is fundamentally different in three ways that matter for safety evaluation.

First, NAD-dependent enzymes called sirtuins (SIRT1-7) are tightly coupled to cell proliferation and differentiation. SIRT1 in particular regulates embryonic and postnatal growth signaling through IGF-1 pathways [4]. Artificially elevating NAD flux during active tissue growth could theoretically perturb sirtuin activity in ways that adult-focused trials would never detect, because adult tissues are no longer undergoing the same proliferative programs.

Second, the PARP family of DNA repair enzymes consumes NAD at high rates during gestation and early childhood, when DNA replication is most frequent. PARP1 activity in rapidly dividing pediatric tissue is substantially higher than in quiescent adult tissue [5]. Supplementing the NAD precursor pool in a child may shift competitive substrate availability between repair pathways in ways that are entirely uncharacterized.

Third, the tryptophan-to-NAD de novo synthesis pathway, the Preiss-Handler pathway, and the salvage pathway all have age-dependent enzyme expression profiles. Children aged 2 to 10 show a different ratio of NAMPT (the rate-limiting enzyme in the salvage pathway) expression compared to adults over 40 [6]. This means the pharmacokinetic response to an NMN or NR dose would likely differ from what adult trials have measured, and no pediatric pharmacokinetic model currently exists to predict that difference.

What Niacin Data Tells Us (and Its Limits as a Proxy)

Niacin and nicotinamide are structurally related to NMN and NR and share parts of the same metabolic pathway. Their pediatric safety profiles provide some limited context, though they are not direct substitutes for NMN/NR data.

The Institute of Medicine established a tolerable upper intake level (UL) for niacin of 10 mg/day for children aged 1-3, and 15 mg/day for children aged 4-8 [7]. These ULs were set to prevent flushing, hepatotoxicity, and glucose dysregulation. They apply to niacin (nicotinic acid), not to NMN or NR directly, but they underscore that even closely related NAD-pathway compounds carry dose-dependent risks in children.

Pharmacologic niacin has been used in children with familial hypercholesterolemia and rare inborn errors of niacin metabolism, but always at carefully monitored doses under specialist supervision, with regular liver function testing [8]. There is no equivalent clinical monitoring protocol for NMN or NR in pediatric populations, because no such protocol has been developed.

One adult NR trial, the ChromaDex-sponsored CALERIE-adjacent study by Martens et al. (2020, N=140), used 1 to 000 mg/day NR and reported elevated blood pressure in a subset of participants at higher doses [9]. Whether a child's cardiovascular system would respond similarly, or more adversely, is unknown. The study enrolled adults aged 55-79 exclusively.

FDA Regulatory Status and What It Means for Pediatricians

The FDA's regulatory posture on NMN creates a specific problem for any clinician considering recommending it for a child. Because the FDA concluded in January 2023 that NMN does not qualify as a dietary supplement under 21 U.S.C. 321(ff)(3)(B)(ii), it cannot legally be sold as one [3]. A pediatrician who recommends an NMN product is effectively recommending an unapproved drug. That carries liability implications beyond the ordinary off-label supplement conversation.

NR does not face the same exclusion, and products like Tru Niagen (ChromaDex) and Elysium Basis remain on the market. However, the FDA has not issued any pediatric labeling requirement for NR, no pediatric clinical investigation plan has been published, and neither the American Academy of Pediatrics (AAP) nor the American Academy of Family Physicians (AAFP) has issued guidance supporting NR supplementation in children.

The Pediatric Research Equity Act (PREA) requires pediatric studies for drugs that seek FDA approval for adult indications, but NR is sold as a supplement, not a drug, so PREA does not compel pediatric investigation [10]. The practical result: there is no regulatory or commercial incentive driving the safety studies that would be needed to make an evidence-based recommendation.

Growth and Developmental Risks: A Framework for Clinical Assessment

When a parent or clinician asks whether NMN or NR is safe for a child under 12, the risk assessment should proceed across four domains. No single domain alone is disqualifying, but all four together currently point in the same direction.

Domain 1: Pharmacokinetic unknowns. Oral NMN in adults is rapidly converted to NMN in the gut lumen and absorbed primarily as NR and NAM (nicotinamide). Pediatric gut enzyme expression patterns differ from adults, meaning the ratio of absorbed species may differ [6]. Without a published pediatric PK study, a prescribing clinician has no basis for selecting a dose, assessing peak plasma exposure, or predicting the duration of elevated NAD metabolites.

Domain 2: Endocrine interactions. The growth hormone (GH) axis operates at its highest activity during childhood. SIRT1, which NMN activates by raising NAD, directly deacetylates and activates FOXO transcription factors that interact with IGF-1 signaling [4]. Theoretical upregulation of SIRT1 activity during the GH-sensitive window of childhood carries an unquantified risk. No animal study has specifically examined this interaction during the postnatal growth window using doses proportional to those in human adult trials.

Domain 3: Oncologic considerations. NAD is consumed by PARPs and sirtuins during DNA damage response. In pediatric oncology, the NAD pathway is already a target of investigation. NAMPT inhibitors, which reduce NAD synthesis, are being studied as antitumor agents in pediatric cancers [11]. The inverse intervention, raising NAD through precursor supplementation, has not been studied in pediatric cancer survivors or in children with subclinical genetic predispositions to cancer. Given that some childhood cancers are driven partly by aberrant proliferative signaling, flooding the NAD pool without oncologic oversight is not a risk-neutral act.

Domain 4: Psychosocial and behavioral confounds. Parents who seek NAD precursor supplements for children under 12 often do so after reading adult longevity content or after a diagnosis of ADHD, autism spectrum disorder, or mitochondrial dysfunction. None of those conditions have peer-reviewed evidence supporting NMN or NR as a treatment. Recommending against supplementation must be paired with redirection toward evidence-based interventions for those conditions.

Rare Pediatric Metabolic Disorders Involving the NAD Pathway

There is one narrow clinical context where NAD-pathway supplementation in children has been formally studied: rare inborn errors of NAD metabolism. NADSYN1 deficiency (vertebral, cardiac, renal, and limb defects syndrome, VACTERL-like) and HAAO/KYNU deficiency cause severe NAD depletion in utero and postnatally. Case series and small open-label studies have explored NAD precursor supplementation in these children, but using nicotinamide (vitamin B3) rather than NMN or NR, and only in specialist metabolic disease centers [12].

These disorders are diagnosed through whole-exome sequencing and confirmed by plasma NAD metabolomics. They are not conditions a parent could or should self-diagnose, and the therapeutic use of NAD precursors in these rare cases provides no justification for supplementing a healthy child.

The European Journal of Human Genetics reported in 2021 that supplementing pregnant mothers with NAD precursors in animal models of NADSYN1 deficiency prevented congenital defects, but the human data remain limited to fewer than 50 published cases worldwide [12]. Extrapolating from this exceptional disease context to healthy children taking longevity supplements is clinically inappropriate.

What Published Guidelines Actually Say

No major medical organization has published a guideline recommending NMN or NR for any pediatric indication.

The American Academy of Pediatrics' 2023 supplement safety statement notes that dietary supplements marketed to children are frequently under-regulated, that label accuracy for potency and purity is inconsistent, and that clinicians should apply particular caution with compounds that lack pharmacokinetic data in children [13].

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy specifically excludes NAD-pathway supplements from its recommendations and does not address their use in children [14]. The guideline notes: "Evidence for supplementation strategies targeting NAD metabolism in human obesity is insufficient to support clinical recommendations." That statement was made in the context of adults. The evidentiary bar for pediatric recommendations is higher still.

The North American Menopause Society, whose members conduct some of the most active NMN/NR clinical research, restricts all its current NMN/NR position statements to postmenopausal women, explicitly noting that no data exist for younger populations [15].

Supplement Quality and Contamination Risks in Pediatric Use

Even setting aside biological unknowns, supplement quality presents a concrete safety risk for children. A 2020 analysis of 30 commercially available NMN products found that 23 contained less NMN than stated on the label, with some products delivering as little as 40% of the claimed dose [2]. Others contained undisclosed compounds. Children, who have lower body mass and less metabolic reserve than adults, are more vulnerable to both under-dosing (which creates a false sense of therapeutic effect) and over-dosing (which raises toxicity risk relative to body weight).

No NMN or NR product currently sold in the United States carries NSF International Certified for Sport, USP Verified, or Informed Sport certification for pediatric purity standards. The absence of third-party certification in a product category with known label inaccuracy problems should be a hard stop for any clinician considering off-label pediatric use.

Clinical Decision Points for Practitioners

A clinician who encounters a parent requesting NMN or NR for a child under 12 should address four specific questions in sequence.

Does the child have a confirmed, genetically diagnosed inborn error of NAD metabolism? If yes, refer immediately to a metabolic disease specialist. NMN and NR are not the standard of care even in that context; nicotinamide is, but a specialist must make that call.

Is the parent seeking NMN or NR for a neurodevelopmental condition such as ADHD or autism? If yes, explain that no trial has tested NMN or NR in those conditions in any age group, and redirect toward evidence-based behavioral and pharmacologic interventions.

Is the parent seeking NMN or NR based on adult longevity content? If yes, explain that NAD declines with age in adults, not in children, and that the biological rationale for these supplements does not apply to a 4-year-old or a 10-year-old.

Is there a mitochondrial disease diagnosis? If yes, the standard supplementation approach involves CoQ10, riboflavin, and thiamine under specialist guidance. Substituting NMN or NR for established mitochondrial support protocols is outside current standard of care.

In none of these scenarios is NMN or NR supplementation appropriate without enrollment in an IRB-approved clinical trial with defined safety monitoring endpoints.